News und Analysen
EQS-News: Invitation to virtual Annual General Meeting of Commerzbank on 31 May 2023
EQS-News: Invitation to virtual Annual General Meeting of Commerzbank on 31 May 2023
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: HOUSING WITH A VISION: TAG IMMOBILIEN AG PUBLISHES SUSTAINABILITY REPORT 2022
EQS-News: HOUSING WITH A VISION: TAG IMMOBILIEN AG PUBLISHES SUSTAINABILITY REPORT 2022
EQS-News: KION Group off to a strong start in fiscal year 2023
EQS-News: KION Group off to a strong start in fiscal year 2023
EQS-Adhoc: KION GROUP AG: Adjusted EBIT and free cash flow at Group level in Q1 2023 better than expected due to strong ITS segment; order volume in SCS segment below market expectations; outlook 2023 increased
EQS-Adhoc: KION GROUP AG: Adjusted EBIT and free cash flow at Group level in Q1 2023 better than expected due to strong ITS segment; order volume in SCS segment below market expectations; outlook 2023 increased
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
CTS EVENTIM founds EDGE, a paid media agency for the entertainment market
CTS EVENTIM founds EDGE, a paid media agency for the entertainment market
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-News: Nagarro releases audited financial results for 2022, announces share buyback
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
EQS-Adhoc: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 30 million euros
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: HELLA increases sales by more than 14 percent in the first quarter
EQS-News: HELLA increases sales by more than 14 percent in the first quarter
Why MongoDB Stock Popped Today
Shares of MongoDB (NASDAQ: MDB) were moving higher today after the database software specialist got an analyst upgrade, and seemed to benefit from a weaker-than-expected inflation report.
As a
Why Investors Are Hating These 2 Nasdaq Stocks Wednesday
2023 has been a good year for the Nasdaq Composite (NASDAQINDEX: ^IXIC) so far, with the index having recovered a significant portion of its 2022 losses. However, it still has a long way to go
Why Shares of Peloton Are Falling Today
Shares of the exercise equipment company Peloton (NASDAQ: PTON) traded roughly 12.3% lower as of 11:33 a.m. ET today after analysts at Morgan Stanley put out a note suggesting that the company saw